

Curriculum Vitae



Prof. Dr. Thomas L. Mindt, PD

Personal Data:

Date of Birth: May 27th 1969

Place of Birth: Summit (NJ), USA

Nationality: CH

Address:

Schumanngasse 16/10

1180 Vienna, Austria

e-mail:

thomas.mindt@lbiad.lbg.ac.at

Professional Assignments

- 2020-present *Professor in Bioinorganic Radiochemistry*, Department of Inorganic Chemistry, Faculty of Chemistry, **University of Vienna**, Vienna (AT); affiliated with the **Medical University of Vienna** (AT), 2021-present: Radiation safety officer
- 2016-present *Co-Founder of the Ludwig Boltzmann Institute Applied Diagnostics and Head of Imaging Biomarkers*, **Ludwig Boltzmann Society**, Vienna (AT)
- 2017-2020 *Lecturer (Privat Dozent)*, Department of Inorganic Chemistry, Faculty of Chemistry, **University of Vienna**, Vienna (AT)
- 2015-2016 *Visiting Professor in Radiopharmaceutical Sciences* (Sabbatical), **ETH Zurich** (CH)
- 2009-2015 *Assistant Professor in Radiopharmaceutical Chemistry*, **University of Basel**, (CH)
- 2005-2009 *Senior Scientist* (2007-2009), *Postdoctoral Fellow* (2005-2006), **ETH Zurich** (CH)
- 2002-2004 *Principle Scientist*, **Physical Science Inc.**, Andover, MA (US, 2004), and **Absolute Science**, Cambridge, MA (US, 2003)

Academia

- 2020 *Primo Loco*, Professorship in Bioinorganic Radiochemistry, **University of Vienna** (AT); call accepted
- 2020 *Secundo Loco*, Professorship in Experimental Radiopharmacy, **University of Duisburg-Essen** (DE)
- 2019 *Tertio Loco*, Professorship in Bioinorganic and Radiopharmaceutical Chemistry, **Technical University of Dresden** and Head of the Institute of Radiopharmaceutical Research, **Helmholtz Centre Dresden-Rossendorf** (DE)
- 2018 *Habilitation* in Radiochemistry (*Venia Legendi*), **University of Vienna** (AT)
- 2015-present *Honorary Professor* in Radiopharmaceutical Chemistry (*Venia Legendi*), **University of Basel** (CH)
- 2009 *Primo Loco*, Professorship in Radiopharmaceutical Chemistry, **University of Basel** (CH); call accepted

Education

- 1998 - 2002 *Ph.D.* in Organic Synthetic Chemistry, **Brown University**, Providence, RI (US)
- 1993 - 1997 *Eidg. Dipl. Chemical Engineer FH* (M.Sc.) with Double Major in Organic Chemistry and Biotechnology, **University of Applied Science**, Winterthur (CH)

Honors and Awards

- 2021 Fellowship for Visiting Scientists and Scientists on Sabbatical Leave of The Scientific and Technological Research Council of Turkey (TUBITAK).
- 2019 Best Article Award of the *European Journal of Nuclear Medicine and Molecular Imaging* (Springer), **32nd Congress of the European Association of Nuclear Medicine**, Barcelona (ES); see publication number 24
- 2007 Young Investigator Award, Society of Radiopharmaceutical Sciences, **17th International Symposium on Radiopharmaceutical Sciences**, Aachen (DE)
- 2001 **Brown University** Dissertation Fellowship, Providence, RI (US)
- 1998 - 2001 Fellow of the Graduate Assistance in Areas of National Need Program of the US Department of Education, **Brown University**, RI (US)
- 2000 Elected Member of the Scientific Research Society Sigma Xi (US)
- 1999 William T. King Prize for Outstanding Performance as a Teaching Assistant, **Brown University**, Providence, RI (US)
- 1998 Dr. Max Lüthi Honor (Swiss Chemical Society) for the Best FH-Diploma Thesis in Chemistry 1997, **ETH Zürich** (CH)
- 1997 SVCT-Prize (Swiss Association of Chemists HTL) for the Best Diploma Grade in Chemistry, **University of Applied Science ZHW**, Winterthur (CH)

Member of Professional Associations

- 2017-present Austrian Society of Nuclear Medicine and Molecular Imaging
- 2017-present Austrian Society of Chemistry
- 2011-present Society of Nuclear Medicine and Molecular Imaging
- 2010-present European Society of Molecular Imaging
- 2008-present European Association of Nuclear Medicine and Molecular Imaging
- 2007-present DE/AT/CH Working Group Radiopharmacy/Radiopharmaceutical Chemistry
- 2006-2016 Swiss Society of Radiopharmacy/Radiopharmaceutical Chemistry
- 2005-present Society of Radiopharmaceutical Sciences
- 1999-present American Chemical Society, Division of Organic Chemistry
- 1999-2014 Sigma Xi the Scientific Research Society, Elected Member
- 1998-present Swiss Chemical Society






Activities in Organisations and Board Memberships

- 2018-present Editorial Board Member of *Nuclear Medicine and Biology*, Journal of the International Society of Radiopharmaceutical Sciences, Elsevier
- 2018-present Editorial Board Member of *Molecules*, a Journal of MDPI
- 2018-present Vice-Chair and Founding Board Member of the *European Society of Radiopharmacy and Radiopharmaceuticals* (ESRR)
- 2012-2019 Member of the Radiopharmacy Committee (Scientific Advisor), *European Association of Nuclear Medicine* (EANM): Publishing guidelines and position papers on topics of current interest for the community
- 2013-2019 Member of the Scientific Program Committee, *EANM*: Organisation of scientific and continuous medical education (CME) sessions and pre-symposia for EANM congresses; abstract reviewing
- 2012-2014 Swiss National Radiopharmacy Delegate, *EANM*: Evaluation and feedback to various publications of EANM committees
- 2011-2016 Member of the Swiss Examination Board of Module III "Radiopharmacy for MDs", *Swiss Society of Radiopharmacy/Radiopharmaceutical Chemistry*

Funding (since 2009 as an independent investigator), **Total approx. MEUR 16**

| | |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2022-2025 | Principle Investigator, Austrian Science Fund (FWF): "Bi-Metallic Complexes for Synergistic and Theranostic Applications" (with Prof. G. Gasser, Chimie ParisTech, FR), Nr. I5721 |
| 2020-2024 | Co-Investigator, Austrian Science Fund (FWF): "Impact of the K-Ras Status on the Activity of Albumin-Targeted Anticancer Drugs" (PI: Prof. P. Heffeter of MUW Cancer Center), Nr. P32886-B |
| 2020-2024 | Principle Investigator, Bridge-1 of the Austrian Research Promotion Agency (FFG): "Radiostar: Novel Chelators for Radio-Lanthanides and-Actinides" (with TUWien and DSD-Pharma GmbH, AT), Nr. 880630 |
| 2018-2022 | Principle Investigator, Austrian Science Fund (FWF), AT: "Improved Tumour Targeting with Radiolabelled Peptido-mimetics" (with Dr. W. Kandoller, UniVie) |
| 2018-2022 | Principle Investigator, Industry collaboration with Orano (FR): "Investigations Toward Novel Chelating Systems for Radium-223 for Targeted Alpha (α) Therapies" (with Prof. G. Gasser, Chimie ParisTech, FR) |
| 2016-2023 | Co-Founder of the Ludwig Boltzmann Institute Applied Diagnostics, Ludwig Boltzmann Society, AT (with Profs M. Mitterhauser, G. Egger, M. Zeitlinger, and J. Simon (Medical University of Vienna, AT)) |
| 2015-2019 | Principle Investigator, Swiss National Science Foundation (SNSF), CH: "Verbessertes Tumor-Targeting mit Radioaktiv-Markierten Peptidomimetika" (Nr. 2021_157076/1); Patent 2017EP17192428 |
| 2015-2019 | Principle Investigator (with Co-Investigator Prof. Gilles Gasser, University of Zurich, Switzerland), Swiss National Science Foundation (SNSF), CH: "Neue Multidentate Bifunktionale Chelator Systeme für die Entwicklung von Zirkonium-89 Basierenden Molekularen Bildgebungsproben" (Nr. 205321_157216/1); Patent WO2015140212A1 |
| 2014-2016 | Principal Investigator, Cancer League Basel, CH: Development of ^{99m}Tc -Tricarbonyl-Based Radiotracers with Improved Pharmacokinetic Profiles for Efficient Tumor Targeting" |
| 2014-2015 | Co-Applicant (PI: Prof. M. Gotthardt, Radboud University, The Netherlands), EU FP7-HEALTH Project: "betaCure" (Nr. 602812) |
| 2013-2015 | Principal Investigator, Novartis-University of Basel Excellence Scholarship for Life Sciences, CH: "Development of Novel GLP-1 Receptor Targeting Radiopeptides for Diagnosis and Therapy of Insulinomas" |
| 2012-2013 | Principal Investigator, Cancer League Basel, CH: "Novel Antagonistic Radiopeptide Mimetics for the Diagnosis and Therapy of Cancer" (Nr. 12-2012) |
| 2011-2013 | Principal Investigator, T. & L. La Roche Foundation, CH: "Development of Zirconium-89 Based Radiopharmaceuticals for the PET Imaging of Insulinoma" |
| 2011-2015 | Principal Investigator, Swiss National Science Foundation (SNSF), CH: "Neuartige radioaktiv-markierte Peptidomimetika für Tumor Targeting" (Nr.205321_132280/1) |
| 2010-2012 | Principal Investigator, Nora van Meeuwen Stiftung, CH: "Radioaktiv-markierte Peptid Analoga für Nuklearmedizinische Anwendungen" |

Appendix I: Publications and Patents

| | | | | | | |
|-----------|------|-----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| | All |  |  |  |  |  |
| Citations | 3232 | | | | | |
| h-index | 28 | | | | | |
| i10-index | 52 | | | | | |

A) Peer-Reviewed Publications

1. "First-in-human brain imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-¹¹C-Me-NB1 PET" L. Rischka, C. Vracka, V. Pichler, S. Rasul, L. Nics, G. Gryglewski, P. Handschuh, M. Murgas, G. N. Godbersen, L. Silberbauer, M. Unterholzner, C. Wotawa, A. Haider, H. Ahmed, R. Schibli, T. L. Mindt, M. Mitterhauser, W. Wadsak, A. Hahn, R. Lanzenberger, M. Hacker, S. M. Ametamey *Journal of Nuclear Medicine* **2021**, on-line. <https://doi.org/10.2967/jnumed.121.262427>
2. "The Race for Hydroxamate-Based Zirconium-89 Chelators" I. V. J. Feiner, M. Brandt, J. Cowell, T. Demuth, D. Vugts, G. Gasser and T. L. Mindt *Cancers* **2021**, *13*, 4466 (*invited review*). DOI: <https://doi.org/10.3390/cancers13174466>
3. "Unexpected transformation of n.c.a. [¹¹¹In]InCl₃ in stock solutions into an unreactive ¹¹¹In-species" C. Giammei, N. Jouini, M. R. Brandt, S. Frey, T. L. Mindt, J. Cardinale *Applied Radiation and Isotopes* **2021**, *180*, 110037-110040. DOI: doi.org/10.1016/j.apradiso.2021.110037
4. "Quality Risk Management Guidelines Applied to Radiopharmaceuticals" N. Gillings, S. Todde, M. Behe, C. Decristoforo, P. Elsinga, V. Ferrari, O. Hjelstuen, P. Kolenc-Peitl, J. Koziorowski, P. Laverman, T. L. Mindt, E. Ocak, M. Patt *European Journal of Nuclear Medicine and Molecular Imaging - Radiopharmacy and Chemistry* **2021**, submitted.
5. "Development and in vitro evaluation of new bifunctional ⁸⁹Zr-chelators based on the 6-amino-1,4-diazepane scaffold for immuno-PET applications" B. Klasen, D. Lemcke, T. L. Mindt, G. Gasser, F. Rösch *Nuclear Medicine and Biology* **2021**, on-line. <https://doi.org/10.1016/j.nucmedbio.2021.06.007>
6. "Improved Tumor-Targeting with Peptidomimetic Analogs of Minigastrin ¹⁷⁷Lu-PP-F11N" N. M. Grob, R. Schibli, M. Béhé, T. L. Mindt *Cancers* **2021**, *13*, 2629 *accepted*. DOI: doi.org/10.3390/cancers13112629
7. "1,5-Disubstituted 1,2,3-Triazoles as Amide Bond Isosteres Yield Novel Tumor-Targeting Minigastrin Analogs" N. M. Grob, R. Schibli, M. Behe, I. E. Valverde, T. L. Mindt *Medicinal Chemistry Letters* **2021**, *12*, 585-592. DOI: [10.1021/acsmchemlett.0c00636](https://doi.org/10.1021/acsmchemlett.0c00636)
8. "Guideline on Current Good Radiopharmacy Practice (cGRPP) for the Small-Scale Preparation of Radiopharmaceuticals – Revision 2019" N. Gillings, S. Todde, M. Behe, C. Decristoforo, P. Elsinga, V. Ferrari, O. Hjelstuen, P. Kolenc-Peitl, J. Koziorowski, P. Laverman, T. L. Mindt, E.

- Ocak, M. Patt *European Journal of Nuclear Medicine and Molecular Imaging - Radiopharmacy and Chemistry* **2021**, 6:8. DOI: 10.1186/s41181-021-00123-2
9. "Single Peptide Backbone Surrogate Mutations to Regulate GPCR Subtype Selectivity" E. I. Vrettos, I. E. Valverde, A. Mascarini, P. N. Pallier, M. Fragai, G. Parigi, B. Hirmiz, N. Bekas, N. M. Grob, E. Stylos, M. Del Borgo, M.-I. Aguilar, F. Magnani, N. Syed, T. Crook, E. Waqif, E. Ghazaly, R. E. Widdop, C. Luchinat, A. T. Michael-Titus, T. L. Mindt, A. G. Tzakos *Chemistry – A European Journal* **2020**, on-line (*highlighted as cover page illustration, shared corresponding authorship T. L. M. and A. G. T.*). DOI: 10.1002/chem.202000924
 10. "1,4-Disubstituted 1,2,3-Triazoles as Amide Bond Surrogate for the Stabilisation of Linear Peptides with Biological Activity" L. M. Recnik, W. Kandioller, T. L. Mindt *Molecules* **2020**, 25, 3576-3602. DOI: 10.3390/molecules25163576
 11. "Head to Head Comparison of the Next Generation Chelators DFO*-NCS and DFOSquaramide: Selection of the Best Candidate for Clinical ⁸⁹Zr-Immuno-PET" M. Chomet, M. Schreurs, M. J. Bolijn, M. Verlaan, W. Beaino, K. Brown, A. J. Poot, A. D. Windhorst, H. Gill, J. Marik, S. Williams, S. E. Rudd, P. Donnelly, J. Cowell, G. Gasser, T. L. Mindt, G.A.M.S van Dongen, D. J. Vugts *European Journal of Nuclear Medicine and Molecular Imaging* **2020**, 48, 694-707. DOI: 10.1007/s00259-020-05002-7
 12. "Sorbitol as a Polar Pharmacological Modifier to Enhance the Hydrophilicity of ^{99m}Tc-Tricarbonyl-Based Radiopharmaceuticals" C. Giammei, T. Balber, K. Bencurova, J. Cardinale, N. Berroterán-Infante, M. Brandt, N. Jouini, M. Hacker, M. Mitterhauser and T. L. Mindt *Molecules* **2020**, 25, 2680-2694. DOI: 10.3390/molecules25112680
 13. "DFO* and oxoDFO*: Optimized Chelators for ⁸⁹Zr-ImmunoPET Applications" M. Brandt, J. Cowell, M. Briand, G. Gasser, T. L. Mindt *Journal of Biological Inorganic Chemistry* **2020**, on-line. DOI: 10.1007/s00775-020-01800-4
 14. "Design of Radiolabeled Minigastrin Analogs by Multiple Amide-to-Triazole Substitutions for Enhanced Tumor Targeting" N. M. Grob, S. Schmid, R. Schibli, M. Béhé, T. L. Mindt *Journal of Medicinal Chemistry* **2020**, 63, 4496-4505. DOI:10.1021/acs.jmedchem.9b01937
 15. "Triazolo-Peptidomimetics: Novel Radiolabeled Minigastrin Analogs for Improved Tumor Targeting" N. M. Grob, D. Häussinger, X. Deupi, R. Schibli, M. Béhé, T. L. Mindt *Journal of Medicinal Chemistry* **2020**, 63, 4484-4495. DOI:10.1021/acs.jmedchem.9b01936
 16. "EANM Guideline on the Validation of Analytical Methods for Radiopharmaceuticals" N. Gillings, S. Todde, M. Behe, C. Decristoforo, P. Elsinga, V. Ferrari, O. Hjelstuen, P. Kolenc-Peiti, J. Kozirowski, P. Laverman, T. L. Mindt, E. Ocak, M. Patt *European Journal of Nuclear Medicine and Molecular Imaging - Radiopharmacy and Chemistry* **2020**, 5 (1), 7. DOI: 10.1186/s41181-019-0086-z
 17. "Manganese in Medical Imaging – Opportunities and Challenges" M. Brandt, J. Cardinale, I. Rausch, T. L. Mindt *Journal of Labelled Compounds and Radiopharmaceuticals* **2019**, 62, 541-551 (*invited review; among the top 10% of most downloaded papers published between January 2018 and December 2019*). DOI: 10.1002/jlcr.3754
 18. "Mini Review: Targeted Radiopharmaceuticals Incorporating Reversible, Low Molecular Weight Albumin Binders" M. Brandt, J. Cardinale, C. Giammei, X. Guarrotxena, B. Hapfl, N. Jouini, T. L. Mindt *Nuclear Medicine and Biology* **2019**, 70, 46-52 (*invited review*). DOI: 10.1016/j.nucmedbio.2019.01.006

19. "Status of the «Consensus Nomenclature Rules in Radiopharmaceutical Sciences» Initiative" H. H. Coenen, A. D. Geeb, M. Adam, G. Antoni, C. S. Cutler, Y. Fujibayashi, J. M. Jeong, R. H. Mach, T. L. Mindt, V. W. Pike, A., D. Windhorst *Nuclear Medicine and Biology* **2019**, *71*, 19-22. DOI: j.nucmedbio.2019.05.001
20. "Comparison of Desferrioxamine and NODAGA for the Gallium-68 Labeling of Exendin-4" S. A. M. Kaeppli, R. Schibli, T. L. Mindt, M. Behe *European Journal of Nuclear Medicine and Molecular Imaging – Radiopharmacy and Chemistry* **2019**, *4*, 9. DOI: 10.1186/s41181-019-0060-9
21. "An Overview on PET-Radiochemistry: Part 2 - Radiometals" M. Brandt, J. Cardinale, M. Aulsebrook, G. Gasser, T. L. Mindt *Journal of Nuclear Medicine* **2018**, *59*, 1500-1506 (*invited review*). DOI: 10.2967/jnumed.117.190801
22. "A Solid Phase-Assisted Approach for the Facile Synthesis of a Highly Water Soluble Octadentate Zirconium-89 Chelator for Radiopharmaceutical Development" M. Briand, M. Aulsebrook, T. L. Mindt, G. Gasser, *Dalton Transactions* **2017**, *46*, 6387-16389 (*shared corresponding authorship T. L. M. and G. G.*). DOI: 10.1039/C7DT03639F
23. "Amide-to-Triazole Switch vs. In Vivo NEP-Inhibition Approaches to Promote Radiopeptide Targeting of GRPR-Positive Tumors" T. Maina, A. Kaloudi, I. E. Valverde, T. L. Mindt, B. A. Nock *Nuclear Medicine and Biology* **2017**, *52*, 57-62 (*shared corresponding authorship B. A. N. and T. L. M.*). DOI: 10.1016/j.nucmedbio.2017.06.001
24. "Consensus Nomenclature Rules for Radiopharmaceutical Chemistry - Setting the Record Straight" M. Adam, G. Antoni, H. H. Coenen, C. S. Cutler, Y. Fujibayashi, A. D. Gee, J. M. Jeong, R. H. Mach, T. L. Mindt, V. W. Pike, A. Windhorst *Nuclear Medicine and Biology* **2017**, *55*, v-xi. DOI: 10.1016/j.nucmedbio.2017.09.004
25. "Guidance on Validation and Qualification of Processes and Operations Involving Radiopharmaceuticals" S. Todde, P. Kolenc Peitl, P. H. Elsinga, J. Kozirowski, V. Ferrari, M. Ocak, O. Hjelstuen, M. Patt, T. L. Mindt, M. Behe *European Journal of Nuclear Medicine and Molecular imaging - Radiopharmacy and Chemistry* **2017**, *2*, 8. DOI: 10.1186/s41181-017-0025-9
26. "Methoxinine - An Alternative Stable Amino Acid Substitute for Oxidation-Sensitive Methionine in Radiolabeled Peptide Conjugates" N. M. Grob, M. Behe, E. von Guggenberg, R. Schibli, T. L. Mindt *Journal of Peptide Science* **2017**, *23*, 38-44. DOI: 10.1002/psc.2948
27. "Glycated ^{99m}Tc-Tricarbonyl Labelled Peptide Conjugates for Tumour Targeting by Click-to-Chelate" K. Römhild, C. A. Fischer, T. L. Mindt *ChemMedChem* **2017**, *12*, 66-74. DOI: 10.1002/cmdc.201600485
28. "Comparison of the Octadentate Bifunctional Chelator DFO*-pPhe-NCS and the Clinically Used Hexadentate Bifunctional Chelator DFO-pPhe-NCS for ⁸⁹Zr-Immuno-PET" D. J. Vugts, C. Klaver, C. Sewing, A. J. Poot, K. Adamzek, S. Huegli, C. Mari, I. E. Valverde, G. Gasser, T. L. Mindt, G.A.M.S. van Dongen *European Journal of Nuclear Medicine and Molecular Imaging* **2017**, *44*, 286-295 (*shared corresponding authorship D. J. V., G. G., and T. L. M.*). DOI: 10.1007/s00259-016-3499-x (*awarded with the Best Article Award of the Journal of Nuclear Medicine and Molecular Imaging in 2019 - Springer*)

29. "Radiolabeled Analogs of Neurotensin (8-13) Containing Multiple 1,2,3-Triazoles as Stable Amide Bond Mimics in the Backbone" A. Mascarin, I. E. Valverde, T. L. Mindt *Medicinal Chemical Communications* **2016**, *7*, 1640-1646. DOI: 10.1039/c6md00208k
30. "Novel Chemoselective ¹⁸F-Radiolabeling of Thiol-Containing Biomolecules Under Mild Aqueous Conditions" A. Chiotellis, F. Sladojevich, L. Mu, A. Müller Herde, I. E. Valverde, V. Tolmachev, R. Schibli, S. M. Ametamey, T. L. Mindt *Chemical Communications* **2016**, *52*, 6083-6086 (*highlighted in the section Swiss Science Concentrates of Chimia, the journal of the Swiss Chemical Society (Chimia 2016, 70, 455)*). DOI: 10.1039/c6cc01982j
31. "Towards the Optimization of Bombesin-Based Radiotracers for Tumor Targeting" I. E. Valverde, S. Vomstein, T. L. Mindt *Journal of Medicinal Chemistry* **2016**, *59*, 3867-3877. DOI: 10.1021/acs.jmedchem.6b00025
32. "Position Paper on Requirements for Toxicological Studies in the Specific Case of Radiopharmaceuticals" J. Kozirowski, M. Behe, C. Decristoforo, J. Ballinger, P. Elsinga, V. Ferrari, P. Kolenc Peitl, S. Todde, T. L. Mindt *European Journal of Nuclear Medicine and Molecular Imaging – Radiopharmacy and Chemistry* **2016**, *1*, 1-6. DOI: 10.1186/s41181-016-0004-6
33. "Structure-Activity Relationship Studies of Amino Acid Substitutions in Radiolabeled Neurotensin Conjugates" A. Mascarin, I. E. Valverde, T. L. Mindt *ChemMedChem* **2016**, *11*, 102–107 (*highlighted as cover page illustration*). DOI: 10.1002/cmdc.201500468
34. "1,2,3-Triazole Stabilized Neurotensin-Based Radiopeptidomimetics for Improved Tumor Targeting" A. Mascarin, I. E. Valverde, S. Vomstein, T. L. Mindt *Bioconjugate Chemistry* **2015**; *26*, 2143–2152. DOI: 10.1021/acs.bioconjchem.5b00444
35. "Probing the Backbone Function of a Bombesin-Based Radiotracer by an Amide-to-Triazole Substitution Strategy" I. E. Valverde, S. Vomstein, T. L. Mindt *Journal of Medicinal Chemistry* **2015**, *58*, 7475–7484. DOI: 10.1021/acs.jmedchem.5b00994
36. "Development of Gallium-68 and Zirconium-89 Labelled Exendin-4 for the Imaging of Insulinomas by PET" A. Bauman, I. E. Valverde, C. A. Fischer, S. Vomstein, T. L. Mindt *Journal of Nuclear Medicine and Molecular Imaging* **2015**, *56*, 1569-1574. DOI: 10.2967/jnumed.115.159186
37. "Regioselective 1,2-Addition of Organometallic Reagents to Unprotected Juglones" K. A. Parker, T. L. Mindt *Tetrahedron Letters* **2015**, *56*, 3500-3502. DOI: 10.1016/j.tetlet.2014.12.108
38. "An Octadentate Bifunctional Chelating Agent for the Development of Stable Zirconium-89 Based Molecular Imaging Probes" M. Patra, A. Bauman, C. Mari, C. A. Fischer, O. Blacque, D. Häussinger, G. Gasser, T. L. Mindt *Chemical Communications* **2014**, *50*, 11523-11525 (*highlighted in the section Swiss Science Concentrates of Chimia, the journal of the Swiss Chemical Society (Chimia 2014, 68, 820)*). DOI: 10.1039/c4cc05558f
39. "A Bombesin-Shepherdin Radioconjugate Designed for Combined Extra- and Intracellular Targeting" C. A. Fischer, S. Vomstein, T. L. Mindt *Pharmaceuticals* **2014**, *7*, 662-675. DOI: 10.3390/ph7060662
40. "Expression of Different Neurokinin Type 1-Receptor Isoforms in Glioblastoma Multiforme – Implications for Targeted Therapy" D. Cordier, A. Gerber, C. Kluba, A. Bauman, G. Hutter, T. L.

- Mindt, L. Mariani *Cancer Biotherapy & Radiopharmaceuticals* **2014**, *29*, 221-226 ([shared corresponding authorship T. L. M. and D. C.](#)). DOI: 10.1089/cbr.2013.1588
41. "Radiolabeled Antagonistic Bombesin Peptidomimetics for Tumor Targeting" I. E. Valverde, E. Huxol, T. L. Mindt *Journal of Labeled Compounds and Radiopharmaceuticals* **2014**, *57*, 275–278. DOI: doi.org/10.1002/jlcr.3162
 42. "Guidance on Current Good Radiopharmacy Practice for the Small-Scale Preparation Radiopharmaceuticals Using Automated Modules: a European Perspective" J. Aerts, J. R. Ballinger, M. Behe, C. Decristoforo, P. H. Elsinga, A. Faivre-Chauvet, T. L. Mindt, P. Kolenc Peitl, S. C. Todde, J. Kozirowski. *Journal of Labeled Compounds and Radiopharmaceuticals* **2014**, *57*, 615-620. DOI: 10.1002/jlcr.3227
 43. "EANM Guideline for the Preparation of an Investigational Medicinal Product Dossier (IMPD)" S. Todde, A. D. Windhorst, M. Behe, G. Bormans, C. Decristoforo, A. Faivre-Chauvet, V. Ferrari, A. D. Gee, B. Gulyas, C. Halldin, P. Kolenc-Peitl, J. Kozirowski, T. L. Mindt, M. Sollini, J. Vercouillie, J. R. Ballinger, P. H. Elsinga *European Journal of Nuclear Medicine and Molecular Imaging* **2014**, *41*, 2175-2185. DOI: 10.1007/s00259-014-2866-8
 44. "1,2,3-Triazoles as Amide Bond Mimics: Triazole Scan Yields Protease-Resistant Peptidomimetics for Tumor Targeting" I. E. Valverde, A. Bauman, C. A. Kluba, S. Vomstein, M. Walter, T. L. Mindt *Angewandte Chemie International Edition*, **2013**, *52*, 8957-8960 ([highlighted in the section Swiss Science Concentrates of Chimia, the journal of the Swiss Chemical Society \(Chimia 2013, 67\(10\), 738\), and in q&more \(2013, 2, 56\); highlighted on-line at bionity.com, schattenblick.de, news.doccheck.com, and ingentaconnect.com](#)). DOI: 10.1002/anie.201303108
 45. "1,2,3-Triazole als Mimetika der Amid-Bindung: Ein Triazol-Scan führt zu Protease-resistenten Peptidmimetika für das Tumor-Targeting" I. E. Valverde, A. Bauman, C. A. Kluba, S. Vomstein, M. Walter, T. L. Mindt *Angewandte Chemie* **2013**, *125*, 9126-9129 (in German). DOI: 10.1002/ange.201303108
 46. "Effect of a Spacer Moiety on Radiometal Labelled Neurotensin Derivatives" A. Mascarin, I. E. Valverde, T. L. Mindt *Radiochimica Acta* **2013**, *11*, 733-738. DOI: 10.1524/ract.2013.2090
 47. "1,2,3-Triazoles as Amide Bond Surrogates in Peptidomimetics" I. E. Valverde, T. L. Mindt *Chimia* **2013**, *4*, 262-266. DOI: 10.2533/chimia.2013.262
 48. "Click-to-Chelate: Development of Technetium- and Rhenium-Tricarbonyl Labeled Radiopharmaceuticals" C. A. Kluba, T. L. Mindt *Molecules* **2013**, *18*, 3206-3226. DOI: 10.3390/molecules18033206
 49. "Dual-Targeting Conjugates Designed to Improve the Efficacy of Radiolabeled Peptides" C. A. Kluba, A. Bauman, I. E. Valverde, S. Vomstein, T. L. Mindt *Organic & Biomolecular Chemistry* **2012**, *10*, 7594-7602. DOI: 10.1039/c2ob26127h
 50. "Synthesis, Gallium-68 Labeling and Biological Evaluation of DOTA-, NODAGA- and Desferrioxamine-modified Nanoparticles" Q.K.T. Ng, T. Segura, A. Ben-Shlomo, T. Krause, T. L. Mindt, M. A. Walter *Journal of Nano Research* **2012**, *20*, 21-31. DOI: 10.4028/www.scientific.net/JNanoR.20.21
 51. "Fluorescent Gallium and Indium Bis(thiosemicarbazones) and Their Radiolabelled Analogues: Design, Synthesis and Cellular Confocal Fluorescence Imaging Investigations" R. L. Arrowsmith, P. A. Waghorn, A. Bauman, S. K. Brayshaw, Z. Hu, M. W. Jones, G. Kociok-Kohn,

- T. L. Mindt, R. M. Tyrrell, S. W. Botchway, J. R. Dilworth, S. I. Pascu *Dalton Transactions* **2011**, 40, 6238-6252. DOI: 10.1039/c1dt10126a
52. "Convergent Synthesis of 2*H*-Chromenes - a Formal [3+3] Cycloaddition by a One-pot, Three Step Cascade" K. A. Parker, T. L. Mindt *Tetrahedron* **2011**, 67, 9779-9786. DOI: 10.1016/j.tet.2011.09.068
53. "Effect of Amino Acid Infusion on Potassium Serum Levels in Neuroendocrine Tumor Patients Treated with Peptide-Receptor Radionuclide Therapy" G. Giovacchini, G. Nicolas, T. L. Mindt, F. Forrer *European Journal of Nuclear Medicine and Molecular Imaging* **2011**, 38, 1675-1682. DOI: 10.1007/s00259-011-1826-9
54. „Imaging of Activated Macrophages in Experimental Osteoarthritis Using Folate Targeted Animal SPECT/CT“ T. M. Piscaer, C. Müller, T. L. Mindt, E. Lubberts, J. A. N. Verhaar, E. P. Krenning, R. Schibli, M. De Jong, H. Weinans *Arthritis & Rheumatism* **2011**, 63, 1898–1907. DOI: 10.1002/art.30363
55. "Molecular Assembly of Multifunctional Tc-99m Radiopharmaceuticals using "Clickable" Amino Acid Derivatives" T. L. Mindt, H. Struthers, B. Spingler, L. Brans, D. Tourwe, E. Garcia-Garayoa, R. Schibli *ChemMedChem* **2010**, 5, 2026-2038. (*highlighted as cover page illustration; among the most accessed articles between 09/2010-08/2011*). DOI: 10.1002/cmdc.201000342
56. "Concepts for the design of metal chelating systems using the copper catalyzed azide-alkyne cycloaddition" H. Struthers, T. L. Mindt, R. Schibli *Dalton Transactions* **2010**, 39, 675. (*highlighted as cover page illustration*). DOI: 10.1039/b912608b
57. "A Click Chemistry Approach to the Efficient Synthesis of Multiple Imaging Probes Derived from a Single Precursor" T. L. Mindt, C. Müller, F. Stucker, J.-F. Salazar, A. Hohn, T. Mueggler, M. Rudin, R. Schibli *Bioconjugate Chemistry* **2009**, 20, 1940-1949. DOI: 10.1021/bc900276b
58. "A Click Approach to Structurally Diverse Conjugates Containing a Central Di-1,2,3-Triazole Metal Chelate" T. L. Mindt, C. Schweinsberg, L. Brans, A. Hagenbach, U. Abram, D. Tourwé, E. Garcia-Garayoa, R. Schibli *ChemMedChem* **2009**, 4, 529. (*among the top 10 most frequently cited articles of ChemMedChem 2009*). DOI: 10.1002/cmdc.200800418
59. "Evaluation of a Novel Radiofolate in Tumor-Bearing Mice - Promising Prospects for Folate-Based Radionuclide Therapy" C. Müller, T. L. Mindt, M. de Jong, R. Schibli *European Journal of Nuclear Medicine and Molecular Imaging* **2009**, 36, 938. DOI: 10.1007/s00259-008-1058-9
60. "Click Chemistry Radiosynthesis and Preclinical Evaluation of a New ¹⁸F-Labelled Folic Acid Derivative" T. L. Ross, M. Honer, P. Y. H. Lam, T. L. Mindt, V. Groehn, R. Schibli, P. A. Schubiger, S. M. Ametamey *Bioconjugate Chemistry* **2008**, 19, 2462. DOI: 10.1021/bc800356r
61. "Click-to-Chelate: In Vitro and In Vivo Comparison of a ^{99m}Tc(CO)₃-Labeled N(τ)-Histidine Folate Derivative with Its Isostructural, Clicked 1,2,3-Triazole Analogue" T. L. Mindt, C. Müller, M. Melis, M. de Jong, R. Schibli *Bioconjugate Chemistry* **2008**, 19, 1689. (*highlighted as cover page illustration; highlighted on-line in Vertical News Chemicals&Chemistry*). DOI: 10.1021/bc800183r
62. "Click-to-Chelate": Design and Incorporation of Triazole Containing Metal Chelating Systems into Biomolecules of Diagnostic and Therapeutic Interest"; H. Struthers, B. Spingler, T. L. Mindt, R. Schibli *Chemistry – A European Journal* **2008**, 14, 6173. DOI: 10.1002/chem.200702024

63. "Modification of Different IgG1 Antibodies via Glutamine and Lysine using Bacterial and Human Tissue Transglutaminase" T. L. Mindt, V. Jungi, S. Wyss, A. Friedli, G. Pla, I. Novak-Hofer, J. Grünberg, R. Schibli *Bioconjugate Chemistry* **2008**, *19*, 271. DOI: 10.1021/bc700306n
64. "Strategies for the Development of Novel Tumor Targeting Technetium and Rhenium Radiopharmaceuticals" T. L. Mindt, H. Struthers, E. Garcia-Garayoa, D. Desbouis, R. Schibli *Chimia* **2007**, *61*, 725. DOI: 10.2533/chimia.2007.725
65. "Cu(I)-Catalyzed Intramolecular Cyclization of Alkynoic Acids in Aqueous Media - a Click Side Reaction"; T. L. Mindt, R. Schibli *The Journal of Organic Chemistry* **2007**, *72*, 10247. DOI: 10.1021/jo702030e
66. "Click to Chelate: Synthesis and Installation of Metal Chelates into Biomolecules in a Single Step" T. L. Mindt, H. Struthers, L. Brans, T. Anguelov, C. Schweinsberg, V. Maes, D. Tourwé, and R. Schibli *Journal of the American Chemical Society* **2006**, *128*, 15096. ([highlighted on-line in Noteworthy Chemistry of the American Chemical Society](#); [highlighted on-line by the Faculty 1000 Biology Reports](#)). DOI: 10.1021/ja066779f
67. "TESOTf-Induced Rearrangement of Quinolins. Efficient Construction of the Fully functionalized Carbon Skeleton of the Griseusins by a Divergent-Reconvergent Approach"; K. A. Parker, T. L. Mindt, Y.-H. Koh *Organic Letters* **2006**, *8*, 1759. DOI: 10.1021/ol060206q
68. "Heterocycle Annulation of Enolizable Vinyl Quinone Imides. Dihydroquinolines and Quinolines from Thermal 6π -Electrocyclizations and Indoles from Photochemical Cyclizations"; K. A. Parker, T. L. Mindt *Organic Letters* **2002**, *4* (24), 4265. DOI: 10.1021/ol026849x
69. "Electrocyclic Ring Closure of the Enols of Vinyl Quinones. A 2H-Chromene Synthesis"; K. A. Parker, T. L. Mindt *Organic Letters* **2001**, *3* (24), 3875. DOI: 10.1021/ol0167199
70. "Synthesis and Evaluation of Enantiomeric Purity of Protected α -Amino and Peptide Aldehydes"; T. Mindt, U. Michel, F. Dick *Helvetica Chimica Acta* **1999**, *82*, 1960. DOI: 10.1002/(SICI)1522-2675(19991110)82:11<1960::AID-HLCA1960>3.0.CO;2-2
71. "Development of Novel Bioerodible Poly(hydroxyalkylene carbonates)s: A Versatile Class of Polymers for Medical and Pharmaceutical Applications"; M. Acemoglu, S. Bantle, T. Mindt *Macromolecules* **1995**, *28*, 3030. DOI: 10.1021/ma00113a003
72. " α -Sulfinyl Substituted Radicals; II. Stereoselective Inter- and Intramolecular Addition Reactions of Acyclic α -Sulfinyl Radicals"; A. De Mesmaeker, A. Waldner, P. Hoffmann, T. Mindt *Synlett* **1993**, *11*, 871. DOI: 10.1055/s-1993-22638
73. " α -Sulfinyl Substituted Radicals; I. Stereoselective Radical Addition Reactions of Cyclic α -Sulfinyl Radicals"; A. Waldner, A. De Mesmaeker, P. Hoffmann, T. Mindt, T. Winkler *Synlett* **1991**, *2*, 101. DOI: 10.1055/s-1991-20642
74. "Stereoselectiv Carbon-Carbon Bond Formation in Carbohydrates by Radical Cyclization Reactions"; A. De Mesmaeker, A. Waldner, P. Hoffmann, T. Mindt, P. Hug, T. Winkler *Synlett* **1990**, *11*, 687. DOI: 10.1055/s-1990-21212

B) Patents

75. "Diaza-18-Crown-6 Derivatives Useful for Chelation of Radium, Conjugates and Radium Chelates Compromising the Same, and Uses Thereof" T. L. Mindt, G. Gasser, M. Brandt, J. Cowell *submitted*

76. "Calixarene Derivatives Useful for Chelation of Radium, Conjugates and Radium Chelates Compromising the Same, and Uses Thereof" T. L. Mindt, G. Gasser, M. Brandt, J. Cowell **2020EP20305646.0**
77. "Minigastrin Derivatives, in Particular for Use in CCK2 Receptor Positive Tumour Diagnosis and/or Treatment" T. L. Mindt, N. M. Grob, M. Behe, R. Schibli **2017EP17192428**
78. "Multidentate Chelating Agents for Radionuclide Complexation in Diagnostics and Therapy" T. L. Mindt, G. Gasser, A. Bauman, M. Patras **WO2015140212A1**
79. "Bombesin Receptor Targeting Peptide Incorporating a 1,2,3-Triazole Group in the Backbone for Preparing In Vivo Diagnostic and Therapeutic Agents" T. L. Mindt, I. Valverde **WO2012/156511**
80. "Novel ¹⁸F-labelled Folates as PET Tracers" T. Ross; T. L. Mindt; V. Groehn; R. Moser; S. Ametamey; A. P. Schubiger **WO2008125615**.
81. "Folic Acid Functionalized with Histidine- or Histidine-like Metal Chelators for SPECT Applications" T. L. Mindt, C. Müller, R. Schibli, V. Groehn **WO2008125618**.
82. "Preparation of Triazole Containing Metal Chelating Agents as well as Their Incorporation into Biomolecules and Their Tricarbonyl Complexes with Technetium and Rhenium" T. L. Mindt, R. Schibli **2006P12660EP**.

C) Book Chapters

83. "Bioconjugation Techniques in Radiopharmaceutical Sciences" J. Cardinale, C. Giammei, N. Jouini, T. L. Mindt in *Radiopharmaceutical Chemistry*, Editors: J. Lewis, B. Zeglis, A. Windhorst, Springer **2019**, 449-466.
84. "Application of Click Chemistry for the Design of Ligand Systems and Functionalization of Biomolecules Suitable for Radiolabelling with the Technetium and Rhenium Tricarbonyl Core" T. Mindt, H. Struthers, R. Schibli in *Technetium-99m Radiopharmaceuticals: Status and Trends*, **2010**, International Atomic Energy Agency, 41-55.

D) Non-Peer-Reviewed Publications

85. "Radioaktive Moleküle gegen Krebs" T. L. Mindt UniVie on-line Newsletter **2021**
86. "Development of Novel Ruthenium-Based Radiopharmaceuticals" B. Happl, M. Brandt, T. Balber, P. Heffeter, Z. Talip, A. Vögele, R. Hasler, M. Jakupcek, R. Schibli, M. Mitterhauser, B. Keppler, W. Kandjoller, N. P. van der Meulen, T. L. Mindt *Annual Research Report of the Paul Scherrer Institute* **2019**, Villigen, Switzerland
87. "Letter to the Editor: International Consensus Radiochemistry Nomenclature Guidelines " M. Adam, G. Antoni, H. H. Coenen, C. S. Cutler, Y. Fujibayashi, A. D. Gee, J. M. Jeong, R. H. Mach, T. L. Mindt, V. W. Pike, A. Windhorst *Current Radiopharmaceuticals* **2018**, *11*, 73-75. DOI: 10.2174/187447101101180404111248
88. "Letter to the Editor: International Consensus Radiochemistry Nomenclature Guidelines " M. Adam, G. Antoni, H. H. Coenen, C. S. Cutler, Y. Fujibayashi, A. D. Gee, J. M. Jeong, R. H. Mach, T. L. Mindt, V. W. Pike, A. Windhorst *American Journal of Nuclear Medicine and Molecular Imaging* **2018**, *8*, 70-72.
89. "Novel Chemoselective ¹⁸F-Radiolabeling of Thiol-Containing Biomolecules Under Mild Aqueous Conditions" A. Chiotellis, F. Sladojevich, L. Mu, A. Müller Herde, I. E. Valverde, V. Tolmachev, R. Schibli, S. M. Ametamey, T. L. Mindt *Chimia* **2016**, *70*, 455 ([Swiss Science Highlight](#)).

90. "Diagnostik und Behandlung von Erkrankungen mit Röntgenstrahlen und radioaktiven Substanzen" F. Zimmermann, D. Wild, T. L. Mindt *Brochure for the Special Exhibition of the Pharmacy-Historical Museum Basel on Radioactivity in Medicine*, **2014** (in German).
91. „Nuklearmedizin - Radioaktive Strahlen können bei Krebspatienten Gutes bewirken“ P. Hofmeier *Basellandschaftliche Zeitung* (in German), October **2014** (newspaper article; editors T. L. Mindt, D. Wild).
92. "An Octadentate Bifunctional Chelating Agent for the Development of Stable Zirconium-89 Based Molecular Imaging Probes" M. Patra, A. Bauman, C. Mari, C. A. Fischer, O. Blacque, D. Häussinger, G. Gasser, T. L. Mindt *Chimia* **2014**, *68*, 820 (*Swiss Science Highlight*).
93. „Heilende Radioaktivität - Das Unispital Basel behandelt Krebspatienten aus der ganzen Welt mit radioaktiven Medikamenten“ P. Hofmeier *Solothurner Zeitung* (in German), October **2014** (newspaper article; editors T. L. Mindt, D. Wild).
94. "1,2,3-Triazoles as Amide Bond Mimics: Triazole Scan Yields Protease-Resistant Peptidomimetics for Tumor Targeting" I. E. Valverde, A. Bauman, C. A. Kluba, S. Vomstein, M. Walter, T. L. Mindt *Chimia* **2013**, *67*(10), 738 (*Swiss Science Highlight*).
95. "Monoclonal Antibody and Peptide-Targeted Radiotherapy of Cancer" (Edited by Raymond M. Reilly), T. L. Mindt, F. Forrer, *ChemMedChem* **2011**, *7*, 202 (book review).
96. "Nanoprobes - Size does matter!" T. L. Mindt, M. Walter *Schweizerisches Medizin-Forum* **2009**, *9*, 51 (*Schlaglichter*).
97. "Click-to-Image: Development of Multiple Probes for Different Imaging Modalities from a Single Precursor" T. Mindt, T. Ross, T. Müggler, C. Müller, M. Honer, P. Lam, F. Stucker, S. Ametamey, M. Rudin, P. A. Schubiger, R. Schibli, *CIMST report* **2008**
98. „An Invention for New Tumour Diagnostics“; T. L. Mindt, H. Struthers, R. Schibli *Paul Scherrer Institute Scientific Report, Highlights Radiopharmacy* **2007**, 48.
99. "Radiopharmazie und Krebsforschung"; T. L. Mindt *À JOUR* **2007**, 5. (in German)
100. „An Invention for New Tumour Diagnostics“; T. L. Mindt, H. Struthers, R. Schibli *Paul Scherrer Institute Scientific Report, Highlights Radiopharmacy* **2006**, 118.
101. "Click to Chelate": Simultaneous Synthesis and Introduction of Polydentate Metal Chelators into Biomolecules for Radiopharmaceutical Applications" T. L. Mindt, H. Struthers, L. Brans, D. Tourwe, R. Schibli In *Technetium, Rhenium and other metals in chemistry and nuclear medicine*, U. Mazzi (Ed.), S.G.E. Padova (Italy) **2006**, 77-80.
102. "Development of Novel Enzymatic Methods for Amino Acid Specific Modification of Diagnostic and Therapeutic Proteins" S. Jeger, T. L. Mindt, A. Blanc, E. Garcia-Garayoa, R. Schibli In *Technetium, Rhenium and other metals in chemistry and nuclear medicine*, U. Mazzi (Ed.), S.G.E. Padova (Italy) **2006**, 647-648.
103. "Graduate Studies Abroad: "Ein Ph.D. Studium in Chemie an der Brown University in den USA"; T. L. Mindt *À JOUR* **2002**, 1 (6), 15.

E) Published Abstracts

>100 published abstracts from presentations or invited lectures at national and international meetings and congresses.

F) Presentations

- Approx. 40 invited keynote lectures and plenary lectures
- Approx. 40 accepted abstracts for presentations and posters
- Approx. 100 accepted abstracts for presentations and posters as co-author